A simple IV fluid choice could tame pancreatitis severity
NCT ID NCT05781243
First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time
Summary
This trial tests whether the type of IV fluid given to people with acute pancreatitis affects how severe the disease becomes. About 800 adults with acute pancreatitis will be randomly assigned to receive either lactated Ringer's solution or normal saline for at least 48 hours. The goal is to see if one fluid reduces the chance of developing moderately severe or severe pancreatitis, which involves complications or organ failure. The results could lead to a simple, inexpensive change in emergency care worldwide.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- lactated Ringer's solution compared to normal saline, given as intravenous fluid resuscitation for at least 48 hours
- What this could lead to
- If lactated Ringer's proves better, it could become the standard IV fluid for acute pancreatitis, reducing severe complications worldwide at low cost.
- What could go wrong
- Previous studies have shown conflicting results, and this trial is open-label, which may introduce bias. The benefit, if any, may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
812 people
The number who actually took part.
- Started
-
Jun 2023
- Finished
-
Aug 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient is 18 years or older * Diagnosis of acute pancreatitis according to the revision of the Atlanta classification (Banks et al, Gut 2013), which requires at least two of the following three criteria: A) typical abdominal pain, B) increase in serum amylase or lipase levels higher than three times the upper limit of normality, and C) signs of acute pancreatitis in imaging * Signature of informed consent Exclusion Criteria: * New York Heart Association class II heart failure (slight limitation of physical activity; fatigue, palpitations, or dyspnea with ordinal physical activity) or worse, or ejection fraction \<50% in the last echocardiography * Decompensated cirrhosis (Child's class B or C) * Hyper or hyponatremia (\<135 or \>145 mEq/L) * Hyperkalemia (\>5 mEq/L) * Hypercalcemia (albumin or protein-corrected calcium \>10.5 mg/dL or 2.62 mmol/L) * Criteria for moderately severe or severe acute pancreatitis (revision of the Atlanta classification, Banks et al, Gut 2013) at recruitment: any of the following: A) presence of creatinine ≥1.9 mg/dL or ≥170 mmol/l, B) PaO2/FiO2≤300, C) systolic blood pressure \<90 mmHg despite initial fluid resuscitation, D) presence of local complications (acute peripancreatic fluid collections, acute necrotic collection, pseudocyst, walled-off necrosis, gastric outlet dysfunction, splenic or portal vein thrombosis, or colonic necrosis), E) exacerbation of previous comorbidity such as coronary artery disease or chronic lung disease, precipitated by the acute pancreatitis * Signs of volume overload or heart failure at recruitment (peripheral edema, pulmonary rales, or increased jugular ingurgitation at 45º) * Time from pain onset to arrival to emergency room \>24 h * Time from confirmation of pancreatitis to randomization \>8 h * Chronic pancreatitis defined by a Wirsung duct ≥4mm and/or pancreatic calcifications * More than 1 previous episode of acute pancreatitis (only 2 episodes of acute pancreatitis are allowed, one of them the present episode)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute pancreatitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dr. Balmis General University Hospital
Alicante, Alicante, 03010, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a vast image library unlock better pancreatic diagnoses?
- Can a single infusion prevent organ failure in severe pancreatitis?
- Blood cell ratios may flag dangerous pancreatitis early
- Can we predict acute pancreatitis outcomes?
- Ancient herbal combo could speed healing in pancreatitis
- Blood test could spot deadly pancreatic infection earlier